Skip to main content

CancerGuide, Duke Ink PGx Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CancerGuide Diagnostics has signed a research collaboration and license agreement with Duke University focused on the development and commercialization of biomarkers for pharmacogenomic applications, the company said today.

The multi-year agreement gives CancerGuide, which is based near Duke in Durham, NC, exclusive commercial rights to a portfolio of validated molecular signatures that predict patient response to certain therapeutics, as well as access to new molecular discoveries made at the private university.

CancerGuide will use these technologies with its pharmaceutical partners in the drug development process and to develop and market diagnostics through an existing agreement it has with LabCorp.

"CancerGuide has begun a well-characterized genomic knowledge database compiled from years of clinical studies," Geoffrey Ginsburg, director of the Center for Genomic Medicine in the Duke Institute for Genome Sciences and Policy, said in a statement. Ginsburg added that the database "will give drug developers the highest level of actionable data and precision to enhance the likelihood of clinical success of their targeted therapeutics."

Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.